Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04233749
PHASE2

The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

Sponsor: Henry Ford Health System

View on ClinicalTrials.gov

Summary

There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

5

Start Date

2020-03-17

Completion Date

2025-12-30

Last Updated

2025-09-09

Healthy Volunteers

No

Interventions

DRUG

Tranexamic acid tablets

325mg of tranexamic acid twice daily for six months

Locations (1)

New Center One

Detroit, Michigan, United States